Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Every quarter in 2024 was better than the last. M&A ended the year on a strong, positive note, with the industrials and TMT ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Investment firm Bain Capital said on Friday that it has signed an agreement to acquire Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group (OTCPK:MTLHY) for approximately 510 billion JPY (3.3 ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...